Raffaella Buzzetti
Sapienza Università di Roma
H-index: 62
Europe-Italy
Top articles of Raffaella Buzzetti
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
IDegLira for the real‐world treatment of type 2 diabetes in Italy. Final results from the REX observational study | Diabetes, Obesity and Metabolism | Gian Paolo Fadini Raffaella Buzzetti Dario Pitocco Elena Tortato Alessia Scatena | 2024/2/8 |
Validation in type 2 diabetes of a metabolomic signature of all‐cause mortality | Diabetes/Metabolism Research and Reviews | Massimiliano Copetti Marco Giorgio Baroni Raffaella Buzzetti Maria Gisella Cavallo Efiso Cossu | 2024/2 |
An updated algorithm for an effective choice of continuous glucose monitoring for people with insulin-treated diabetes (vol 82, pg215, 2023) | Maria Ida Maiorino Raffaella Buzzetti Concetta Irace Luigi Laviola Nicola Napoli | 2023/11 | |
LADA 30th anniversary: A growing form of diabetes with persistent unresolved questions | Diabetes/Metabolism Research and Reviews | Ivy Lee Jia Jia Raffaella Buzzetti Richard David Leslie Paolo Pozzilli | 2024/5 |
Saxagliptin/dapagliflozin is non‐inferior to insulin glargine in terms of β‐cell function in subjects with latent autoimmune diabetes in adults: A 12‐month, randomized … | Diabetes, Obesity and Metabolism | Ernesto Maddaloni Anda M Naciu Carmen Mignogna Raffaele Galiero Rocco Amendolara | 2024/1/31 |
Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes | Ernesto Maddaloni Rocco Amendolara Angela Balena Alessandro Latino Rosario Luigi Sessa | 2024/4/2 | |
Correction: An updated algorithm for an effective choice of continuous glucose monitoring for people with insulin-treated diabetes | Endocrine | Maria Ida Maiorino Raffaella Buzzetti Concetta Irace Luigi Laviola Nicola Napoli | 2024/1/31 |
Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk | The Lancet Regional Health–Europe | Gian Paolo Fadini Enrico Longato Mario Luca Morieri Stefano Del Prato Angelo Avogaro | 2024/3/1 |
MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus | Diabetes & Metabolism | Alessandro Mantovani Mario Luca Morieri Raffaella Aldigeri Luisa Palmisano Maria Masulli | 2024/1/1 |
A sub-analysis of the SAGE study in Italy indicates good glycemic control in type 1 diabetes | Nutrition, Metabolism and Cardiovascular Diseases | D Bruttomesso C Irace P Pozzilli Roberto Anichini Alice Magiar | 2023/3/1 |
L’eterogeneità del meccanismo autoimmune che conduce al diabete tipo 1 giustifica il fallimento dell’immunoterapia? | Silvia Pieralice Luca D’Onofrio Raffaella Buzzetti | 2023/6 | |
Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus | Cardiovascular Diabetology | Alessandro Mantovani Mario Luca Morieri Luisa Palmisano Maria Masulli Efisio Cossu | 2023/8/10 |
Glycated haemoglobin in the first year after diagnosis of type 1 diabetes is an independent risk factor for diabetic retinopathy: The IMDIAB 25 years follow-up study | Diabetes, obesity & metabolism | Ernesto Maddaloni Angela Carlone Dario Pitocco Giulia Leanza Concetta Suraci | 2023/11 |
Domande aperte sul ruolo dell’insulina basale nel trattamento del diabete di tipo 2: una Delphi expert consensus | Delphi Board Raffaella Buzzetti Riccardo Candido Katherine Esposito Andrea Giaccari | 2023 | |
Impact of baseline kidney function on the effects of sodium‐glucose co‐transporter‐2 inhibitors on kidney and heart failure outcomes: A systematic review and meta‐analysis of … | Ernesto Maddaloni Ilaria Cavallari Ylenia La Porta Alessandro Appetecchia Luca D'Onofrio | 2023/5 | |
Association between different modalities of insulin administration and metabolic dysfunction-associated fatty liver disease in adults with type 1 diabetes mellitus | Diabetes & Metabolism | Alessandro Csermely Alessandro Mantovani Mario Luca Morieri Luisa Palmisano Maria Masulli | 2023/11/1 |
Terapia con inibitori del checkpoint immunitario e rischio di diabete di tipo 1 | L'Endocrinologo | Alessandro Latino Raffaella Buzzetti | 2023/8 |
Corrigendum to Comparative effectiveness of Glargine 300 U/mL vs. Degludec 100 U/mL in patients with type 2 diabetes switching from 1° generation basal insulins> Nutr Metab … | Nutrition, metabolism, and cardiovascular diseases: NMCD | Raffaella Buzzetti Gian Paolo Fadini Antonio Nicolucci Monica Larosa Maria Chiara Rossi | 2023/4 |
Diabetes, COVID‐19, and questions unsolved | Felecia D’Souza Raffaella Buzzetti Paolo Pozzilli | 2023/7 | |
Lack of Association between Serum Chitotriosidase Activity and Arterial Stiffness in Type 2 Diabetes without Cardiovascular Complications | International Journal of Molecular Sciences | Luca D’Onofrio Rocco Amendolara Carmen Mignogna Gaetano Leto Lida Tartaglione | 2023/10/31 |
